⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GILD News
Gilead Sciences Inc
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate
globenewswire.com
KYMR
GILD
SAS Innovate 2026 to feature new health care and life sciences AI capabilities and real-world use cases
prnewswire.com
JNJ
AZN
GILD
REGN
SNY
IQV
OGN
PFE
ABBV
ELV
CI
EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion USA - English USA - English
prnewswire.com
GILD
EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion
prnewswire.com
GILD
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
businesswire.com
GILD
Next Generation Drug Conjugates (NDCs) Market worth $42.55 billion by 2035 | MarketsandMarkets™
prnewswire.com
ALNY
GILD
IONQ
ABBV
ARWR
Centri Announces Panel Topics and Featured Programming for Second Annual Capital Conference at Nasdaq on April 14
accessnewswire.com
NDAQ
DFIN
PTGX
STRL
TNDM
AXSM
CSTL
CYTK
GILD
INSM
KODK
NBIX
OCGN
REGN
SRPT
VRTX
XBIT
AMZN
GOOGL
MSFT
NVDA
IBM
ORGN
BWEN
CCJ
EXC
NEE
SO
UTL
XOM
BALY
OXY
PBF
CHRD
AX
BAC
MAXN
PHIO
KZR
SMX
DUOT
COIN
EHTH
Global Virus Network Meeting Advances a Science-Driven Agenda for Pandemic Preparedness
globenewswire.com
PFE
MRK
JNJ
BMY
GILD
Gilead Extends Tender Offer to Acquire Arcellx
businesswire.com
GILD
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides
accessnewswire.com
NNVC
GILD
SIGA
EBS